MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases

H. Kh Haider, Y. Lei, Muhammad Ashraf

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials.

Original languageEnglish (US)
Pages (from-to)611-621
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume10
Issue number6
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Skeletal Myoblasts
Cardiovascular Diseases
Safety
Phase II Clinical Trials
Clinical Trials, Phase I
Cell- and Tissue-Based Therapy
Therapeutics
Catheters
Heart Failure
Myocardial Infarction

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. / Haider, H. Kh; Lei, Y.; Ashraf, Muhammad.

In: Current Opinion in Molecular Therapeutics, Vol. 10, No. 6, 01.12.2008, p. 611-621.

Research output: Contribution to journalReview article

@article{e148462450a64f629b2998593d89c0a2,
title = "MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases",
abstract = "Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials.",
author = "Haider, {H. Kh} and Y. Lei and Muhammad Ashraf",
year = "2008",
month = "12",
day = "1",
language = "English (US)",
volume = "10",
pages = "611--621",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "6",

}

TY - JOUR

T1 - MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases

AU - Haider, H. Kh

AU - Lei, Y.

AU - Ashraf, Muhammad

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials.

AB - Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=57349090903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349090903&partnerID=8YFLogxK

M3 - Review article

C2 - 19051139

AN - SCOPUS:57349090903

VL - 10

SP - 611

EP - 621

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 6

ER -